Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout.

Novartis is reportedly nearing a takeover of Cytokinetics. Cytokinetics’ stock surged following positive trial results for its drug, aficamten, in patients with a progressive disease leading to heart failure. The stock continued to climb, with Novartis stock also rising. Aficamten is being compared to Bristol Myers Squibb’s Camzyos, which generated $68 million in worldwide sales in the latest quarter. Cytokinetics CEO Robert Blum highlighted the advantages of aficamten over Camzyos, including a shorter half-life and simplified dosage administration. Analysts have expressed optimism about Cytokinetics’ stock following the positive trial results.